Bone effects of biologic drugs in rheumatoid arthritis

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Corrado, Addolorata ^a   Neve, Anna ^a   Maruotti, Nicola ^a   Cantatore, Francesco Paolo ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 17; INTERLEUKIN 6; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; IMMUNOLOGIC FACTOR;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; BIOLOGICAL THERAPY; BONE DENSITY; BONE METABOLISM; BONE REMODELING; CHRONIC INFLAMMATION; DISEASE ACTIVITY; DISEASE CONTROL; DRUG INDICATION; FRACTURE; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BONE; DISEASE COURSE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; JOINT; PATHOLOGY; PREVENTION AND CONTROL; RADIOGRAPHY; DRUG ANTAGONISM; DRUG EFFECT;

ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BONE AND BONES; BONE RESORPTION; DISEASE PROGRESSION; GENE EXPRESSION; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-6; JOINTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84880174207     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/945945     Document Type: Review

References (62)

1. Spector T. D., Hall G. M., McCloskey E. V., Kanis J. A., Risk of vertebral fracture in women with rheumatoid arthritis. British Medical Journal 1993 306 6877 558 2-s2.0-0027452820 (Pubitemid 23056878)
2. Gough A. K. S., Lilley J., Eyre S., Holder R. L., Emery P., Generalised bone loss in patients with early rheumatoid arthritis. The Lancet 1994 344 8914 23 27 2-s2.0-0028305241 10.1016/S0140-6736(94)91049-9 (Pubitemid 24199420)
3. Bernstein C. N., Blanchard J. F., Leslie W., Wajda A., Yu B. N., The incidence of fracture among patients with inflammatory bowel disease: a population-based cohort study. Annals of Internal Medicine 2000 133 10 795 I50 2-s2.0-0034700291
4. Bultink I. E. M., Lems W. F., Kostense P. J., Dijkmans B. A. C., Voskuyl A. E., Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis and Rheumatism 2005 52 7 2044 2050 2-s2.0-22244459190 10.1002/art.21110 (Pubitemid 40994328)
5. Oostlander A. E., Everts V., Schoenmaker T., Bravenboer N., van Vliet S. J., van Bodegraven A. A., Lips P., de Vries T. J., T cell-mediated increased osteoclast formation from peripheral blood as a mechanism for crohn's disease-associated bone loss. Journal of Cellular Biochemistry 2012 113 1 260 268 2-s2.0-84055218377 10.1002/jcb.23352
6. Colucci S., Brunetti G., Cantatore F. P., Oranger A., Mori G., Quarta L., Cirulli N., Mancini L., Corrado A., Grassi F. R., Grano M., Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNF α and IL-7 in an in vitro model derived from human psoriatic arthritis. Journal of Pathology 2007 212 1 47 55 2-s2.0-34248582794 10.1002/path.2153 (Pubitemid 46746289)
7. Wilkison M., Gauss K., Ran Y., Searles S., Taylor D., Meissner M., Type 1 interferons suppress accelerated osteoclastogenesis and prevent loss of bone mass during systemic inflammatory responses to Pneumocystis lung infection. The American Journal of Pathology 2012 81 151 162
8. Hardy R., Cooper M. S., Bone loss in inflammatory disorders. Journal of Endocrinology 2009 201 3 309 320 2-s2.0-67849119581 10.1677/JOE-08-0568
9. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., Kollias G., Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO Journal 1991 10 13 4025 4031 2-s2.0-0026039673 (Pubitemid 21905432)
10. Eggelmeijer F., Papapoulos S. E., Westedt M. L., van Paassen H. C., Dijkmans B. A. C., Breedveld F. C., Bone metabolism in rheumatoid arthritis: relation to disease activity. British Journal of Rheumatology 1993 32 5 387 391 2-s2.0-0027277015 (Pubitemid 23181991)
11. Sambrook P. N., The skeleton in rheumatoid arthritis: common mechanisms for bone erosion and osteoporosis? Journal of Rheumatology 2000 27 11 2541 2542 2-s2.0-0033738784
12. Sambrook P., Tumour necrosis factor blockade and the risk of osteoporosis: back to the future. Arthritis Research and Therapy 2007 9 4, article 107 2-s2.0-34548444980 10.1186/ar2277 (Pubitemid 47354917)
13. Kruppa G., Thoma B., Machleidt T., Wiegmann K., Krönke M., Inhibition of tumor necrosis factor (TNF)-mediated NF- B activation by selective blockade of the human 55-kDa TNF receptor. Journal of Immunology 1992 148 10 3152 3157 2-s2.0-0026561071
14. Gravallese E. M., Manning C., Tsay A., Naito A., Pan C., Amento E., Goldring S. R., Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis and Rheumatism 2000 43 2 250 258 (Pubitemid 30395732)
15. Lam J., Takeshita S., Barker J. E., Kanagawa O., Ross F. P., Teitelbaum S. L., TNF- α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. Journal of Clinical Investigation 2000 106 12 1481 1488 2-s2.0-0034523328 (Pubitemid 32038586)
16. Fuller K., Murphy C., Kirstein B., Fox S. W., Chambers T. J., TNF α potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 2002 143 3 1108 1118 2-s2.0-0036008152 10.1210/en.143.3.1108 (Pubitemid 34164059)
17. Komine M., Kukita A., Kukita T., Ogata Y., Hotokebuchi T., Kohashi O., Tumor necrosis factor- α cooperates with receptor activator of nuclear factor B ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. Bone 2001 28 5 474 483 2-s2.0-0035043292 10.1016/S8756-3282(01)00420-3 (Pubitemid 32409998)
18. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Morinaga T., Higashio K., Martin T. J., Suda T., Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. Journal of Experimental Medicine 2000 191 2 275 285 2-s2.0-0034677177 10.1084/jem.191.2.275 (Pubitemid 30060917)
19. Boyce B. F., Schwarz E. M., Xing L., Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease. Current Opinion in Rheumatology 2006 18 4 427 432 2-s2.0-33748091692 10.1097/01.bor.0000231913.32364.32 (Pubitemid 44297290)
20. Gilbert L., He X., Farmer P., Boden S., Kozlowski M., Rubin J., Nanes M. S., Inhibition of osteoblast differentiation by tumor necrosis factor- α Endocrinology 2000 141 11 3956 3964 2-s2.0-0033695186
21. 2-vitamin D3 on TNF α -mediated apoptosis of human primary osteoblast-like cells in vitro. Hormone and Metabolic Research 1999 31 12 653 656 2-s2.0-0033233342 (Pubitemid 30056139)
22. Gilbert L., He X., Farmer P., Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. The Journal of Biological Chemistry 2002 277 4 2695 2701 (Pubitemid 34953297)
23. Lu X., Gilbert L., He X., Rubin J., Nanes M. S., Transcriptional regulation of the osterix (Osx, Sp7) promoter by tumor necrosis factor identifies disparate effects of mitogen-activated protein kinase and NF B pathways. Journal of Biological Chemistry 2006 281 10 6297 6306 2-s2.0-33646588049 10.1074/jbc.M507804200 (Pubitemid 43847561)
24. Diarra D., Stolina M., Polzer K., Zwerina J., Ominsky M. S., Dwyer D., Korb A., Smolen J., Hoffmann M., Scheinecker C., van der Heide D., Landewe R., Lacey D., Richards W. G., Schett G., Dickkopf-1 is a master regulator of joint remodeling. Nature Medicine 2007 13 2 156 163 2-s2.0-33846949349 10.1038/nm1538
25. Kotake S., Yago T., Kawamoto M., Nanke Y., Role of osteoclasts and interleukin-17 in the pathogenesis of rheumatoid arthritis: crucial 'human osteoclastology'. Journal of Bone and Mineral Metabolism 2012 30 2 125 135 2-s2.0-84859833805 10.1007/s00774-011-0321-5
26. Adamopoulos I. E., Tessmer M., Chao C.-C., Adda S., Gorman D., Petro M., Chou C.-C., Pierce R. H., Yao W., Lane N. E., Laface D., Bowman E. P., IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. Journal of Immunology 2011 187 2 951 959 2-s2.0-79960492398 10.4049/jimmunol.1003986
27. Maruotti N., Grano M., Colucci S., d'Onofrio F., Cantatore F. P., Osteoclastogenesis and arthritis. Clinical and Experimental Medicine 2011 11 3 137 145 2-s2.0-80054948463 10.1007/s10238-010-0117-2
28. le Goff B., Blanchard F., Berthelot J.-M., Heymann D., Maugars Y., Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine 2010 77 3 201 205 2-s2.0-77952672784 10.1016/j.jbspin.2010.03.002
29. Polzer K., Joosten L., Gasser J., Distler J. H., Ruiz G., Baum W., Redlich K., Bobacz K., Smolen J. S., van den Berg W., Schett G., Zwerina J., Interleukin-1 is essential for systemic inflammatory bone loss. Annals of the Rheumatic Diseases 2010 69 1 284 290 2-s2.0-73449088382 10.1136/ard.2008.104786
30. Ma Y., Thornton S., Boivin G. P., Hirsh D., Hirsh R., Hirsh E., Altered susceptibility to collagen-induced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist. Arthritis & Rheumatism 1998 41 1798 1805 (Pubitemid 28465533)
31. van den Berg W. B., Uncoupling of inflammatory and destructive mechanisms in arthritis. Seminars in Arthritis and Rheumatism 2001 30 5, supplement 2 7 16 2-s2.0-0035306510 10.1053/sarh.2001.23704 (Pubitemid 32467130)
32. van den Berg W. B., Arguments for interleukin 1 as a target in chronic arthritis. Annals of the Rheumatic Diseases 2000 59 supplement 1 i81 i84 2-s2.0-0033764203
33. Houssiau F. A., Devogelaer J.-P., van Damme J., Nagant de Deuxchaisnes C., van Snick J., Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis and Rheumatism 1988 31 6 784 788 2-s2.0-0023942493
34. Steiner G., Tohidast-Akrad M., Witzmann G., Vesely M., Studnicka-Benke A., Gal A., Kunaver M., Zenz P., Smolen J. S., Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology 1999 38 3 202 213 2-s2.0-0032703306 10.1093/rheumatology/38.3.202 (Pubitemid 29507155)
35. Hashizume M., Mihara M., The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis 2011 2011 8 10.1155/2011/765624 765624
36. Karsdal M. A., Schett G., Emery P., Harari O., Byrjalsen I., Kenwright A., Bay-Jensen A. C., Platt A., IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Seminars in Arthritis and Rheumatism 2012 42 2 131 139 2-s2.0-84857660096 10.1016/j.semarthrit.2012. 01.004
37. Zwerina J., Tuerk B., Redlich K., Smolen J. S., Schett G., Imbalance of local bone metabolism in inflammatory arthritis and its reversal upon tumor necrosis factor blockade: direct analysis of bone turnover in murine arthritis. Arthritis Research & Therapy 2006 8 1 R22 2-s2.0-36349005105
38. Stolina M., Schett G., Dwyer D., Vonderfecht S., Middleton S., Duryea D., Pacheco E., Van G., Bolon B., Feige U., Zack D., Kostenuik P., RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNF α or anti-IL-1 therapies. Arthritis Research and Therapy 2009 11 6, article R187 2-s2.0-77952531784 10.1186/ar2879
39. Saidenberg-Kermanac'h N., Corrado A., Lemeiter D., deVernejoul M. C., Boissier M. C., Cohen-Solal M. E., TNF- α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 2004 35 5 1200 1207 2-s2.0-8444236292 10.1016/j.bone.2004.07.004 (Pubitemid 39487367)
40. Ritchlin C. T., Haas-Smith S. A., Li P., Hicks D. G., Schwarz E. M., Mechanisms of TNF- α-and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. Journal of Clinical Investigation 2003 111 6 821 831 2-s2.0-0037364369 10.1172/JCI200316069 (Pubitemid 37074957)
41. Torikai E., Kageyama Y., Takahashi M., Suzuki M., Ichikawa T., Nagafusa T., Nagano A., The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis. Rheumatology 2006 45 6 761 764 2-s2.0-33745595892 10.1093/rheumatology/kei280 (Pubitemid 43985348)
42. Vis M., Havaardsholm E. A., Haugeberg G., Uhlig T., Voskuyl A. E., van de Stadt R. J., Dijkmans B. A. C., Woolf A. D., Kvien T. K., Lems W. F., Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NF B ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2006 65 11 1495 1499 2-s2.0-33749150667 10.1136/ard.2005.044198 (Pubitemid 44629129)
43. Lange U., Teichmann J., Müller-Ladner U., Strunk J., Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF- α antibody: a prospective open-label pilot study. Rheumatology 2005 44 12 1546 1548 2-s2.0-28544447762 10.1093/rheumatology/kei082 (Pubitemid 41742473)
44. Chopin F., Garnero P., le Henanff A., Debiais F., Daragon A., Roux C., Sany J., Wendling D., Zamitsky C., Ravaud P., Thomas T., Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2008 67 3 353 357 2-s2.0-39549116297 10.1136/ard.2007.076604 (Pubitemid 351281270)
45. Haugeberg G., Conaghan P. G., Quinn M., Emery P., Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Annals of the Rheumatic Diseases 2009 68 12 1898 1901 2-s2.0-72249085325 10.1136/ard.2008.106484
46. Eekman D. A., Vis M., Bultink I. E. M., Kuik D. J., Voskuyl A. E., Dijkmans B. A. C., Lems W. F., Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2011 70 2 389 390 2-s2.0-78751694016 10.1136/ard.2009.127787
47. Wijbrandts C. A., Klaasen R., Dijkgraaf M. G. W., Gerlag D. M., van Eck-Smit B. L. F., Tak P. P., Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Annals of the Rheumatic Diseases 2009 68 3 373 376 2-s2.0-61449164945 10.1136/ard.2008.091611
48. Vis M., Voskuyl A. E., Wolbink G. J., Dijkmans B. A. C., Lems W. F., Bone mineral density in patients with rheumatoid arthritis treated with infliximab. Annals of the Rheumatic Diseases 2005 64 2 336 337 2-s2.0-13244294174 10.1136/ard.2003.017780 (Pubitemid 40193646)
49. Marotte H., Pallot-Prades B., Grange L., Gaudin P., Alexandre C., Miossec P., A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Research and Therapy 2007 9 3, article R61 2-s2.0-34548443592 10.1186/ar2219
50. Eekman D. A., Vis M., Bultink I. E. M., Kuik D. J., Voskuyl A. E., Dijkmans B. A. C., Lems W. F., Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2011 70 2 389 390 2-s2.0-78751694016 10.1136/ard.2009.127787
51. Güler-Yüksel M., Allaart C. F., Goekoop-Ruiterman Y. P. M., de Vries-Bouwstra J. K., van Groenendael J. H. L. M., Mallée C., de Bois M. H. W., Breedveld F. C., Dijkmans B. A. C., Lems W. F., Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Annals of the Rheumatic Diseases 2009 68 3 330 336 2-s2.0-61449124076 10.1136/ard.2007.086348
52. Dirven L., Güler-Yüksel M., de Beus W. M., Ronday H. K., Speyer I., Huizinga T. W. J., Dijkmans B. A. C., Allaart C. F., Lems W. F., Changes in hand bone mineral density and the association with the level of disease activity in patients with rheumatoid arthritis: bone mineral density measurements in a multicenter randomized clinical trial. Arthritis Care and Research 2011 63 12 1691 1699 2-s2.0-84856021377 10.1002/acr.20612
53. Hoff M., Kvien T. K., Kälvesten J., Elden A., Kavanaugh A., Haugeberg G., Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study. BMC Musculoskeletal Disorders 2011 12 article 54 2-s2.0-79951952034 10.1186/1471-2474-12-54
54. Ricciardi B. F., Paul J., Kim A., Russell L. A., Lane J. M., Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease. Osteoporosis International 2013 24 2 423 432 10.1007/s00198-012-2113-8
55. Kim S. Y., Schneeweiss S., Liu J., Solomon D. H., Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study. Journal of Bone and Mineral Research 2012 27 4 789 796 2-s2.0-84858733450 10.1002/jbmr.1489
56. Kremer J. M., Blanco R., Brzosko M., Burgos-Vargas R., Halland A.-M., Vernon E., Ambs P., Fleischmann R., Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis and Rheumatism 2011 63 3 609 621 2-s2.0-79953680176 10.1002/art.30158
57. Garnero P., Thompson E., Woodworth T., Smolen J. S., Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis and Rheumatism 2010 62 1 33 43 2-s2.0-74849102659 10.1002/art.25053
58. Joosten L. A. B., Helsen M. M. A., Saxne T., van de Loo F. A. J., Heinegård D., van den Berg W. B., IL-1 α β blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF- α blockade only ameliorates joint inflammation. Journal of Immunology 1999 163 9 5049 5055 2-s2.0-0032752705 (Pubitemid 29501273)
59. Bendele A., McAbee T., Sennello G., Frazier J., Chlipala E., McCabe D., Efficacy of sustained blood levels of interelukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis & Rheumatism 1999 42 498 506 (Pubitemid 29136098)
60. Bresnihan B., Alvaro-Garcia J. M., Cobby M., Treatment of rheumatoid arthritis with recombinant human IL-1ra. Arthritis & Rheumatism 1998 41 12 2196 2204 (Pubitemid 29009378)
61. Kimble R. B., Vannice J. L., Bloedow D. C., Thompson R. C., Hopfer W., Kung V. T., Brownfield C., Pacifici R., Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. Journal of Clinical Investigation 1994 93 5 1959 1967 2-s2.0-0028206914 (Pubitemid 24143073)
62. Charatcharoenwitthaya N., Khosla S., Atkinson E. J., McCready L. K., Riggs B. L., Effect of blockade of TNF- α and interleukin-1 action on bone resorption in early postmenopausal women. Journal of Bone and Mineral Research 2007 22 5 724 729 2-s2.0-34447303828 10.1359/jbmr.070207 (Pubitemid 351339101)